Cash Flow Statement (Annual)

LNT / Alliant Energy Corp. Cash Flow Statement shows changes in cash positions over time. Cash Flow Statement data includes Cash from Operating Activities (CFOP), Cash from Investing Activities, and Cash from Financing Activities.

All numbers are times 1,000 except per share units.

2009 2010 2011 2012 2013 2014 2015 2016 2017
Net Cash Provided By Used In Operating Activities
  Net Income Loss 129,700 306,300 321,900 335,700 376,200 393,300 388,400 381,700 467,500
  Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities
    Depreciation And Amortization 273,600 287,300 323,800 332,400 370,900 388,100 401,300 411,600 461,800
    Depreciation And Amortization Cash Flow - - - - - - - - -
    Adjustment Depreciation And Amortization Including Discontinued Operations 275,600 292,300 323,800 332,900 370,900 388,100 401,300 411,600 461,800
    Other Operating Activities Cash Flow Statement - - - - - 54,200 12,400 -4,800 21,700
    Other Amortization Of Deferred Charges 42,100 51,800 56,300 55,000 40,200 54,200 12,400 - -
    Deferred Income Taxes And Tax Credits 94,300 216,600 10,200 143,300 108,300 55,200 114,200 84,600 139,600
    Income Loss From Equity Method Investments 36,600 38,100 39,300 41,300 43,700 40,400 33,800 39,600 44,800
    Equity Method Investment Dividends Or Distributions 29,900 32,200 32,300 34,200 35,400 36,400 30,600 28,300 38,100
    Other Noncash Income Expense 5,700 4,700 5,200 2,600 3,700 -2,000 -15,700 -800 -6,700
    Increase Decrease In Allowance For Equity Funds Used During Construction 28,200 11,200 7,600 14,100 20,300 23,100 24,400 42,300 33,600
    Impairment Of Long Lived Assets Held For Use - - - - - 0 0 86,400 0
    Non Cash Valuation Charges 20,400 38,000 25,500 3,300 - - - - -
  Increase Decrease In Operating Capital
    Increase Decrease In Accounts Receivable -73,500 -16,300 54,300 -61,300 49,200 -48,700 -36,800 121,400 -29,600
    Increase Decrease In Other Receivables 25,000 -65,000 -75,000 10,000 101,000 7,000 17,000 -16,000 9,000
    Increase Decrease In Income Taxes Receivable 102,300 -130,400 -300 -20,900 - - - - -
    Increase Decrease In Fossil Fuel Inventories 28,500 -17,400 -22,500 - - - - - -
    Gas Stored Underground - - - - - - - - -
    Increase Decrease In Other Regulatory Assets 163,900 20,800 413,100 178,100 -140,500 439,800 104,500 3,600 130,800
    Increase Decrease In Accounts Payable - - - - - - - - -
    Increase Decrease In Regulatory Liabilities 136,700 8,400 168,300 16,400 -90,800 10,800 -67,800 -63,000 -83,800
    Increase Decrease In Income And Other Taxes Payable Noncurrent 60,700 -66,600 -5,100 -2,900 - - - - -
    Increase Decrease In Accrued Taxes Payable 25,800 -32,400 2,000 - - - - - -
    Increase Decrease In Pension And Postretirement Obligations -190,000 -20,100 8,900 51,300 -157,400 215,100 30,100 38,100 -
    Increase Decrease In Derivative Liabilities 16,300 -52,000 10,700 -37,600 - - - - -
    Increase Decrease In Deferred Income Taxes -118,900 -28,900 -148,500 -69,700 -101,900 -138,400 -94,600 -102,400 -81,700
    Increase Decrease In Other Operating Capital Net -10,400 -12,200 -21,100 14,200 -23,700 -59,700 5,400 15,600 -38,700
  Net Cash Provided By Used In Operating Activities 657,100 984,900 702,700 841,100 731,000 891,600 871,200 859,600 983,400
Net Cash Provided By Used In Investing Activities
  Payments To Acquire Productive Assets Business Line1 1,149,600 0 608,100 403,500 0 0 - - -
  Payments To Acquire Productive Assets Business Line2 53,000 33,600 65,300 132,600 66,700 63,900 70,700 54,100 185,100
  Payments To Acquire Productive Assets Other - 833,300 608,100 622,000 731,600 838,900 963,600 1,142,700 1,281,800
  Proceeds From Sale Of Productive Assets - - - - 0 0 139,900 0 0
  Payments For Proceeds From Other Investing Activities 16,600 16,700 4,600 19,900 18,800 14,900 24,800 -10,300 29,400
  Proceeds From Sale Of Wind Project Assets To Affiliate - - - - - - - - -
  Net Cash Provided By Used In Investing Activities -1,148,900 -866,500 -652,100 -1,155,500 -754,700 -917,700 -919,200 -1,186,500 -1,496,300
  Proceeds From Cash Grant - - - 0 62,400 0 0 - -
  Advances For Customer Energy Efficiency Projects 31,000 17,100 5,100 400 - - - - -
  Collections Of Advances For Customer Energy Efficiency Projects 63,600 34,200 31,000 22,900 - - - - -
Net Cash Provided By Used In Financing Activities
  Payments Of Dividends Common Stock 165,500 174,600 188,100 199,300 208,300 225,800 247,300 266,500 288,300
  Proceeds From Issuance Of Common Stock - - - - 0 0 151,200 26,600 149,600
  Payments Of Dividends Preferred Stock And Preference Stock 18,700 18,700 16,800 15,900 11,400 10,200 - - -
  Proceeds From Contributions From Parent - - - - - - - - -
  Repayment Of Capital To Parent - - - - - - - - -
  Payments Of Capital Distribution - - - - - - - - -
  Proceeds From Repayments Of Short Term Debt 103,900 -142,600 55,400 164,700 11,900 -138,100 18,500 84,300 171,100
  Proceeds From Repayments Of Bank Overdrafts - - - - - - - - -
  Payments For Repurchase Of Redeemable Preferred Stock - 0 40,000 0 211,000 0 0 - -
  Proceeds From Payments For Other Financing Activities -21,800 9,300 -8,100 -8,900 -28,800 -7,100 6,800 -1,700 -45,200
  Proceeds From Issuance Of Redeemable Preferred Stock - - - 0 200,000 0 0 - -
  Proceeds From Issuance Of Long Term Debt 800,200 500,000 400 385,000 250,000 812,900 250,700 800,000 550,000
  Net Cash Provided By Used In Financing Activities 320,200 -134,400 -198,500 324,200 12,300 73,200 -3,100 329,300 532,600
  Repayments Of Long Term Debt 377,900 307,800 1,300 1,400 1,500 358,500 183,000 313,400 4,600
Cash And Cash Equivalents Period Increase Decrease -171,600 -16,000 -147,900 9,800 -11,400 47,100 -51,100 2,400 19,700
Cash And Cash Equivalents At Carrying Value - - 11,400 21,200 - 56,900 5,800 8,200 27,900
Supplemental Cash Flow Information
  Interest Paid Net 142,400 165,500 157,600 155,200 171,700 180,800 184,800 192,400 212,600
  Income Taxes Paid Net -140,700 -116,200 -10,800 -20,300 -9,600 -5,300 0 9,800 11,300
  Cash Flow Noncash Investing And Financing Activities Disclosure
    Capital Expenditures Incurred But Not Yet Paid 66,700 75,000 49,700 105,300 103,800 160,300 148,300 154,400 196,500
    Transfer Of Investments - - - - - - - - -

Peers - Electric and Other Services Combined (4931)

Related Articles

RDHL: Redhill Biopharma Ltd (OTC:REDIF) Analysis and Research Report

2018-04-18 - Asif

History and Development of the Company The company's legal and commercial name is RedHill Biopharma Ltd. The company's company was incorporated on August 3, 2009, and was registered as a private company limited by shares under the laws of the State of Israel. The company's principal executive offices are located at 21 Ha’arba’a Street, Tel Aviv, Israel. In February 2011, the company completed its initial public offering in Israel, pursuant to which the company issued 14,302,300 Ordinary Shares, and 7,151,150 tradable Series 1 Warrants to purchase 7,151,150 Ordinary Shares for aggregate gross proceeds of approximately $14 million. On December 27, 2012, the company completed the listing of its ADSs on the NASDAQ Capital Market. The company's Ordinary Shares are traded on the Tel-Aviv Stock Exchange under the symbol “RDHL,” and its ADSs are traded on the NASDAQ Capital Market under the same symbol "RDHL". The company's capital expenditures for the years ended December 31, 2...

SCYX: SCYNEXIS Analysis and Research Report

2018-04-16 - Asif

Overview SCYNEXIS, Inc. is a biotechnology company committed to positively impacting the lives of patients suffering from difficult-to-treat and often life-threatening infections by delivering innovative anti-infective therapies. SCYNEXIS is developing its lead product candidate, SCY-078, as the first representative of a novel oral and intravenous (IV) triterpenoid antifungal family in clinical development for the treatment of several serious fungal infections, including invasive candidiasis, invasive aspergillosis, refractory invasive fungal infections and vulvovaginal candidiasis (VVC). SCY-078 is a structurally distinct glucan synthase inhibitor that has been shown to be effective in vitro and in vivo against a broad range of human fungi pathogens such as Candida and Aspergillus species, including multidrug-resistant strains, as well as Pneumocystis species. Candida and Aspergillus species are the fungi responsible for approximately 85% of all invasive fungal infections in t...

ENRT: Enertopia Corp (CNSX:TOP) Analysis and Research Report

2018-04-16 - Asif

Business History Enertopia Corp. was formed on November 24, 2004 under the laws of the State of Nevada and commenced operations on November 24, 2004. From inception until April 2010, the company were primarily engaged in the acquisition and exploration of natural resource properties. Beginning in April 2010, the company began its entry into the renewable energy sector by purchasing an interest in a solar thermal design and installation company. In late summer 2013, the company began its entry into medicinal marijuana business. During its 2014 fiscal year end its activities in the clean energy sector were discontinued. During fiscal 2015 its activities in the Medicinal Marijuana sector were discontinued. During fiscal 2016 its activities in the Women’s personal healthcare sector were discontinued. The Company is actively pursuing business opportunities in the resource sector, whereby the company signed a definitive agreement for a Lithium Brine Project in May 2016. In May ...

FB: Facebook Analysis and Research Report

2018-04-15 - Asif

Overview The company's mission is to give people the power to build community and bring the world closer together. The company's top priority is to build useful and engaging products that enable people to connect and share with friends and family through mobile devices, personal computers, and other surfaces. The company also help people discover and learn about what is going on in the world around them, enable people to share their opinions, ideas, photos and videos, and other activities with audiences ranging from their closest friends to the public at large, and stay connected everywhere by accessing its products, including: Facebook enables people to connect, share, discover, and communicate with each other on mobile devices and personal computers. There are a number of different ways to engage with people on Facebook, the most important of which is News Feed which displays an algorithmically-ranked series of stories and advertisements individualized for each pers...

VSTM: Verastem Analysis and Research Report

2018-04-12 - Asif

Business Overview Verastem is a biopharmaceutical company focused on developing and commercializing drugs to improve the survival and quality of life of cancer patients. The company's most advanced product candidates, duvelisib and defactinib, utilize a multi-faceted approach to treat cancers originating either in the blood or major organ systems. Verastem is currently evaluating these compounds in both preclinical and clinical studies as potential therapies for certain cancers, including leukemia, lymphoma, lung cancer, ovarian cancer, mesothelioma, and pancreatic cancer. The company believe that these compounds may be beneficial as therapeutics either as single agents or when used in combination with immuno-oncology agents or other current and emerging standard of care treatments in aggressive cancers that are poorly served by currently available therapies. Duvelisib targets the Phosphoinositide 3-kinase (PI3K) signaling pathway. The PI3K signaling pathway plays a centr...

CUSIP: 018802108